The administrative core will be a key component of the success of the Martin Delaney Collaboratory to Eradicate HIV Infection. The power of the Collaboratory will be derived from the strength of its investigators and leading institutions, working in concert across research gaps to bring into clinical testing new molecules and approaches to radication of HIV infection. This Core will supervise the overall activities of this program, providing fiscal accountability, infrastructure and coordination between the laboratory, animal model, and human studies aspects of the Collaboratory. The Core will coordinate intensive communications within the Collaboratory: between the projects, project investigators, NIAID Project Scientist, and the Scientific Advisory Panel, and as needed with other agencies (e.g. FDA). To do this the Core will manage conference calls, web-based tools for meeting, communication, and data-sharing, track the promulgation and publication of study results, produce annual reports, and insure that any resources developed within the Program are appropriately shared outside the Collaboratory. The Core will engage the Scientific Advisory Board, convene Steering Committee, an annual scientific and organizational meeting, and manage intellectual property or other dispute resolution if needed. Further, the core will engage and assist a community advisory board, to garner appropriate support and discussion of the impact of Collaboratory efforts, and address the challenging questions that will arise as human studies begin. The Administrative Core will operationalize the Collaboratory's commitment to pool resources and expertise, transcend the normal constraints of academic research, and work in coordination towards the common goal of eradication of HIV infection.
Despite the success of antiretroviral therapy (ART) in decreasing mortality for HIV-1-infected patients, ART has not cured the disease. A persistent viral reservoir in the T cells of HIV patients receiving potent ART is a significant barrier preventing an HIV cure. Including scientists from eight universities and Merck Research Laboratories, the Martin Delaney Collaboratory will seek to eradicate HIV infection by developing and testing therapies, capable of eventually being tested clinically. that will permanently destroy the viral reservoir.
|White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603|
|Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:|
|Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198|
|Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17|
|Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670|
|Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :|
|Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876|
|Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647|
|Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93|
|Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133|
Showing the most recent 10 out of 221 publications